U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07243782) titled 'Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx(R)(Secukinumab) in Korea' on Nov. 17.
Brief Summary: Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx(R)(secukinumab) in Korea
Study Start Date: Dec. 31
Study Type: OBSERVATIONAL
Condition:
Hidradenitis Suppurativa
Pediatric Plaque Psoriasis
Juvenile Idiopathic Arthritis
Intervention:
DRUG: Secukinumab
This is a prospective observational study. There is no treatment allocation. The decision to initiate treatment will be based so...